Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13

被引：0
|
作者：
Park, Won [1 ]
Miranda, Pedro [2 ,3 ]
Brzosko, Marek [4 ]
Wiland, Piotr [5 ]
Gutierrez-Urena, Sergio [6 ]
Mikazane, Helena [7 ]
Lee, Yeon-Ah [8 ]
Smiyan, Svitlana [9 ]
Lim, Mie-Jin [1 ]
Kadinov, Vladimir [10 ]
Abud-Mendoza, Carlos [11 ,12 ]
Son, YoungKi [13 ]
Yoo, Dae-Hyun [14 ]
Braun, Juergen [15 ]
机构：
[1] Inha Univ Hosp, Inchon, South Korea
[2] Univ Chile, Santiago, Chile
[3] Ctr Estudios Reumatol, Santiago, Chile
[4] Pomeranian Med Univ, Dept Rheumatol & Internal Dis, Szczecin, Poland
[5] Med Univ Wroclaw, Wroclaw, Poland
[6] Antiguo Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico
[7] Outpatient Clin ORTO, Riga, Latvia
[8] Kyung Hee Univ, Seoul, South Korea
[9] Ternopil Univ Hosp, Municipal Inst Ternopil Reg Council, Ternopol, Ukraine
[10] Multiprofile Hosp Act Treatment Sv Marina, Varna, Bulgaria
[11] Univ Autonoma San Luis Potosi, Hosp Cent, San Luis Potosi, Mexico
[12] Univ Autonoma San Luis Potosi, Fac Med, San Luis Potosi, Mexico
[13] CELLTRION, Inchon, South Korea
[14] Hanyang Univ, Hosp Rheumat Dis, Seoul 133791, South Korea
[15] Rheumazentrum Ruhrgebiet, Herne, Germany
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
L15
引用
收藏
页码：3326 / 3326
页数：1
相关论文
共 50 条
  • [31] Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases
    Blair, Hannah A.
    Deeks, Emma D.
    BIODRUGS, 2016, 30 (05) : 469 - 480
  • [32] Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
    Jung, Yoon Suk
    Park, Dong Il
    Kim, Young Ho
    Lee, Ji Hyun
    Seo, Pyoung Ju
    Cheon, Jae Hee
    Kang, Hyoun Woo
    Kim, Ji Won
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (12) : 1705 - 1712
  • [33] Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis
    Farkas, Klaudia
    Rutka, Mariann
    Golovics, Petra A.
    Vegh, Zsuzsanna
    Lovasz, Barbara D.
    Nyari, Tibor
    Gecse, Krisztina B.
    Kolar, Martin
    Bortlik, Martin
    Duricova, Dana
    Machkova, Nadezda
    Hruba, Veronika
    Lukas, Martin
    Mitrova, Katarina
    Malickova, Karin
    Balint, Anita
    Nagy, Ferenc
    Bor, Renata
    Milassin, Agnes
    Szepes, Zoltan
    Palatka, Karoly
    Lakatos, Peter L.
    Lukas, Milan
    Molnar, Tamas
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (11): : 1273 - 1278
  • [34] Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care
    Nikiphorou, E.
    Hannonen, P.
    Asikainen, J.
    Borodina, J.
    Kokko, A.
    Paalanen, K.
    Rannio, T.
    Sokka, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (01) : 55 - 59
  • [35] SWITCHING FROM ORIGINATOR INFLIXIMAB TO CT-P13: A UK SINGLE CENTRE EXPERIENCE
    Bhandare, Anirudh Pramod
    Crooks, Benjamin
    Nigam, Gaurav Bhaskar
    Limdi, Jimmy K.
    GUT, 2019, 68 : A70 - A70
  • [36] Factors associated with anti-drug antibody production in ankylosing spondylitis patients treated with the infliximab biosimilar CT-P13
    Kim, Yongbum
    Choi, Nayeon
    Shin, Ji-Hui
    Jo, Sungsin
    Nam, Bora
    Kim, Tae-Hwan
    JOURNAL OF RHEUMATIC DISEASES, 2025, 32 (02): : 136 - 144
  • [37] Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe
    Mueller-Ladner, Ulf
    Hong, SeungSuh
    Oh, Choongseob
    Taylor, Peter
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 : S5 - S14
  • [38] Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study
    Smith, Philip J.
    Critchley, Lisa
    Storey, Daniel
    Gregg, Belle
    Stenson, June
    Kneebone, Andrew
    Rimmer, Tracy
    Burke, Stevena
    Hussain, Shamas
    Yi Teoh, Wan
    Vazeille, Stephan
    Serna, Solange
    Steel, Alan
    Derbyshire, Edmund
    Collins, Paul
    Dibb, Martyn
    Flanagan, Paul
    Probert, Christopher
    Verma, Ajay M.
    Subramanian, Sreedhar
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (09): : 1436 - 1446
  • [39] Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment
    Gompertz, M.
    Alfaro, I.
    Ricart, E.
    Lopez, A.
    Panes, J.
    Gallego, M.
    Barastegui, R.
    Giner, A.
    Vara, A.
    Masamunt, M.
    Ordas, I.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S427 - S428
  • [40] Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab
    Tanaka, Yoshiya
    Yamanaka, Hisashi
    Takeuchi, Tsutomu
    Inoue, Makoto
    Saito, Kazuyoshi
    Saeki, Yukihiko
    Lee, Sang Joon
    Nambu, Yoshihiro
    MODERN RHEUMATOLOGY, 2017, 27 (02) : 237 - 245
12345